<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01690897</url>
  </required_header>
  <id_info>
    <org_study_id>H12-01659</org_study_id>
    <nct_id>NCT01690897</nct_id>
  </id_info>
  <brief_title>Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women</brief_title>
  <acronym>DESIRE</acronym>
  <official_title>Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an 8-session mindfulness-based intervention&#xD;
      (MBCT group) is effective for women with low sexual interest/desire in reducing sexual&#xD;
      distress, improving their sexual response, and increasing their mindful skills, compared to a&#xD;
      support group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESES:&#xD;
&#xD;
        1. Compared to baseline, the MBCT group will have significant post-treatment improvements&#xD;
           in self-report measures of: (a) sexual distress; (b) sexual desire, subjective sexual&#xD;
           arousal, perception of genital arousal, and sexual pleasure; (c) relationship&#xD;
           satisfaction; (d) depressive symptoms and rumination; (e) perceived stress, general&#xD;
           anxiety, anxiety sensitivity, and sexuality-related situational anxiety (as&#xD;
           self-reported at the sexual arousal assessment); and (f) mindfulness, self-compassion,&#xD;
           non-attachment, and interoceptive awareness.&#xD;
&#xD;
        2. Compared to baseline, the MBCT group will have significant post-treatment improvements&#xD;
           in laboratory physiological measures of: (a) genital sexual response as measured by a&#xD;
           vaginal photoplethysmograph, (b) interoceptive awareness, as measured by a heart rate&#xD;
           perception task, and (c) cortisol:DHEA ratio as measured by hormonal assays of saliva&#xD;
           samples.&#xD;
&#xD;
        3. We hypothesize that the changes in the endpoints listed in #1 or #2 will be&#xD;
           significantly greater in the MBCT group than in the support group.&#xD;
&#xD;
        4. We hypothesize that participation in the MBCT group will significantly increase&#xD;
           concordance between genital and subjective sexual arousal.&#xD;
&#xD;
        5. Mindfulness, self-compassion, and interoceptive awareness will significantly mediate&#xD;
           improvements in sexual distress and desire in the MBCT group at all post-treatment&#xD;
           assessment points.&#xD;
&#xD;
        6. Expectations of change with treatment will not significantly moderate improvements in&#xD;
           sexual distress and desire in the MBCT group.&#xD;
&#xD;
        7. Participants' impressions of change will be significantly greater in the MBCT group&#xD;
           compared to the support group at all post-treatment assessment points.&#xD;
&#xD;
        8. We hypothesize that participants will experience fewer breaks in the sexual response&#xD;
           cycle throughout the course of the eight-week treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual distress</measure>
    <time_frame>up to 12 months post treatment</time_frame>
    <description>Sexual distress will be measured with the revised version of the Female Sexual Distress Scale-R (Derogatis et al., 2008).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective sexual arousal</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Subjects will indicate their levels of subjective arousal while undergoing arousal testing. A device manufactured for the UBC Sexual Health Lab called the &quot;arousometer&quot;- a computer mouse mounted on a metal track divided into 10 equally spaced intervals corresponding to &quot;sexually turned off&quot; (-2) to &quot;the most sexually aroused you have ever been or could imagine being&quot; (7). This device allows continuous self-report measurement of subjective sexual arousal while viewing the erotic films.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interoceptive awareness</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Interoceptive awareness will be measured using the Heartbeat Perception task (Schandry, 1981) and with the Multidimensional Assessment of Interoceptive Awareness (MAIA; Mehling et al., 2012) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological sexual arousal</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Physiological sexual arousal will be measured with a Vaginal Photoplethysmograph (VPP) during exposure to erotic films. The VPP measures vaginal pulse amplitude (VPA) which has been found to be a sensitive and specific measure of genital arousal (Laan &amp; Everaerd, 1995).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual desire</measure>
    <time_frame>Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>The Sexual Interest and Desire Inventory (SIDI; Clayton et al. 2006) will be used to measure sexual desire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress hormone ratios</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Stress hormone ratios will be measured through calculating the cortisol:DHEA slope within participants' saliva samples. This will be done by measuring the change in cortisol:DHEA secretions over the course of the day, and calculating a simple difference score (PM minus AM values).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Depression will be measured with the Hamilton Depression Scale - Short Form (McIntyre et al., 2005)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mindfulness</measure>
    <time_frame>Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Mindfulness will be measured with the Five Factor Mindfulness questionnaire (Baer, Smith, Hopkins, Krietemeyer &amp; Tony, 2006).</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship satisfaction</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Relationship satisfaction will be measured with the Relationship Assessment Scale (Hendrick, 1988).</description>
  </other_outcome>
  <other_outcome>
    <measure>Motivations for sex</measure>
    <time_frame>For Motivations for Sex Measure: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment. Time frame for sexual response cycle worksheet: measured at weeks 2, 5, and 8 of treatment.</time_frame>
    <description>Motivations for sex will be measured with the Motivations for Sex Measure (Muise et al., 2013); disruptions to the sexual response cycle (each cycle is one sexual encounter, specifically the most recent sexual encounter), which will be measured using the Sexual Response Cycle Worksheet (Basson, 2000).</description>
  </other_outcome>
  <other_outcome>
    <measure>Perceived stress</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Perceived stress will be measured with the Perceived Stress Scale (Cohen, Kamarck, &amp; Mermelstein, 1983).</description>
  </other_outcome>
  <other_outcome>
    <measure>Rumination</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Rumination will be measured with the Rumination-Reflection Questionnaire - Adapted Rumination Subscale (adapted from Trapnell &amp; Campbell, 1999 to inquire about sexuality-related rumination).</description>
  </other_outcome>
  <other_outcome>
    <measure>Trait anxiety and situational anxiety</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>At the sexual arousal assessments, which will be measured with the State-Trait Anxiety Inventory (Spielberger, Gorsuch, &amp; Lushene, 1970).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety sensitivity</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Anxiety sensitivity will be measured with the Anxiety Sensitivity Index - 3 (Taylor et al., 2007).</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-compassion</measure>
    <time_frame>Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Self-compassion will be measured with the Self-Compassion Scale (Neff, 2003).</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-attachment</measure>
    <time_frame>Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Non-attachment will be measures with Non-Attachment Scale (Sahdra, Shaver, &amp; Brown, 2010).</description>
  </other_outcome>
  <other_outcome>
    <measure>Expectations of change with treatment</measure>
    <time_frame>Expectations Measure: after session 1. For Patient Global Impression of Change Scale: 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.</time_frame>
    <description>Will be measured with the Expectations Measure [a two-item questionnaire completed following the session 1, designed for and used in our approved mindfulness-based treatment study for provoked vestibulodynia (H12-02358)], and participants' impressions of change with treatment with the Patient Global Impression of Change Scale - Revised (adapted from Hurst &amp; Bolton, 2004; as used in H12-02358).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Low Female Sexual Desire</condition>
  <arm_group>
    <arm_group_label>MBCT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Support group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness-based treatment</intervention_name>
    <description>The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.</description>
    <arm_group_label>MBCT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sex therapy, education, and support treatment</intervention_name>
    <description>The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.</description>
    <arm_group_label>Support group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must be experiencing distressing sexual interest/desire and/or sexual arousal concerns&#xD;
&#xD;
          -  must between the ages of 19 - 65&#xD;
&#xD;
          -  must be fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not experiencing distressing sexual interest/desire and/or sexual arousal concerns&#xD;
&#xD;
          -  not between the ages of 19-65&#xD;
&#xD;
          -  unable to read, write, speak and understand English&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori A Brotto, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gynaecology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>September 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2012</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Lori Brotto</investigator_full_name>
    <investigator_title>Professor, UBC Department of Gynaecology</investigator_title>
  </responsible_party>
  <keyword>Female sexual desire</keyword>
  <keyword>Psychoeducational intervention</keyword>
  <keyword>Mindfulness</keyword>
  <pending_results>
    <submitted>November 1, 2022</submitted>
    <returned>September 12, 2023</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01690897
org study id: H12-01659
nct id: NCT01690897
lead sponsor: 
The purpose of this study is to determine whether an 8-session mindfulness-based intervention
      (MBCT group) is effective for women with low sexual interest/desire in reducing sexual
      distress, improving their sexual response, and increasing their mindful skills, compared to a
      support group.
HYPOTHESES:

        1. Compared to baseline, the MBCT group will have significant post-treatment improvements
           in self-report measures of: (a) sexual distress; (b) sexual desire, subjective sexual
           arousal, perception of genital arousal, and sexual pleasure; (c) relationship
           satisfaction; (d) depressive symptoms and rumination; (e) perceived stress, general
           anxiety, anxiety sensitivity, and sexuality-related situational anxiety (as
           self-reported at the sexual arousal assessment); and (f) mindfulness, self-compassion,
           non-attachment, and interoceptive awareness.

        2. Compared to baseline, the MBCT group will have significant post-treatment improvements
           in laboratory physiological measures of: (a) genital sexual response as measured by a
           vaginal photoplethysmograph, (b) interoceptive awareness, as measured by a heart rate
           perception task, and (c) cortisol:DHEA ratio as measured by hormonal assays of saliva
           samples.

        3. We hypothesize that the changes in the endpoints listed in #1 or #2 will be
           significantly greater in the MBCT group than in the support group.

        4. We hypothesize that participation in the MBCT group will significantly increase
           concordance between genital and subjective sexual arousal.

        5. Mindfulness, self-compassion, and interoceptive awareness will significantly mediate
           improvements in sexual distress and desire in the MBCT group at all post-treatment
           assessment points.

        6. Expectations of change with treatment will not significantly moderate improvements in
           sexual distress and desire in the MBCT group.

        7. Participants' impressions of change will be significantly greater in the MBCT group
           compared to the support group at all post-treatment assessment points.

        8. We hypothesize that participants will experience fewer breaks in the sexual response
           cycle throughout the course of the eight-week treatment.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Sexual distress
time frame: up to 12 months post treatment
description: Sexual distress will be measured with the revised version of the Female Sexual Distress Scale-R (Derogatis et al., 2008).
measure: Subjective sexual arousal
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Subjects will indicate their levels of subjective arousal while undergoing arousal testing. A device manufactured for the UBC Sexual Health Lab called the "arousometer"- a computer mouse mounted on a metal track divided into 10 equally spaced intervals corresponding to "sexually turned off" (-2) to "the most sexually aroused you have ever been or could imagine being" (7). This device allows continuous self-report measurement of subjective sexual arousal while viewing the erotic films.
measure: Interoceptive awareness
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Interoceptive awareness will be measured using the Heartbeat Perception task (Schandry, 1981) and with the Multidimensional Assessment of Interoceptive Awareness (MAIA; Mehling et al., 2012) questionnaire.
measure: Physiological sexual arousal
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Physiological sexual arousal will be measured with a Vaginal Photoplethysmograph (VPP) during exposure to erotic films. The VPP measures vaginal pulse amplitude (VPA) which has been found to be a sensitive and specific measure of genital arousal (Laan & Everaerd, 1995).
measure: Sexual desire
time frame: Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: The Sexual Interest and Desire Inventory (SIDI; Clayton et al. 2006) will be used to measure sexual desire.
measure: Stress hormone ratios
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Stress hormone ratios will be measured through calculating the cortisol:DHEA slope within participants' saliva samples. This will be done by measuring the change in cortisol:DHEA secretions over the course of the day, and calculating a simple difference score (PM minus AM values).
measure: Depression
time frame: Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Depression will be measured with the Hamilton Depression Scale - Short Form (McIntyre et al., 2005)
measure: Mindfulness
time frame: Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Mindfulness will be measured with the Five Factor Mindfulness questionnaire (Baer, Smith, Hopkins, Krietemeyer & Tony, 2006).
measure: Relationship satisfaction
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Relationship satisfaction will be measured with the Relationship Assessment Scale (Hendrick, 1988).
measure: Motivations for sex
time frame: For Motivations for Sex Measure: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment. Time frame for sexual response cycle worksheet: measured at weeks 2, 5, and 8 of treatment.
description: Motivations for sex will be measured with the Motivations for Sex Measure (Muise et al., 2013); disruptions to the sexual response cycle (each cycle is one sexual encounter, specifically the most recent sexual encounter), which will be measured using the Sexual Response Cycle Worksheet (Basson, 2000).
measure: Perceived stress
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Perceived stress will be measured with the Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1983).
measure: Rumination
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Rumination will be measured with the Rumination-Reflection Questionnaire - Adapted Rumination Subscale (adapted from Trapnell & Campbell, 1999 to inquire about sexuality-related rumination).
measure: Trait anxiety and situational anxiety
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: At the sexual arousal assessments, which will be measured with the State-Trait Anxiety Inventory (Spielberger, Gorsuch, & Lushene, 1970).
measure: Anxiety sensitivity
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Anxiety sensitivity will be measured with the Anxiety Sensitivity Index - 3 (Taylor et al., 2007).
measure: Self-compassion
time frame: Up to 2.5 months before treatment, mid-treatment (between week 4 and 5 of treatment), 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Self-compassion will be measured with the Self-Compassion Scale (Neff, 2003).
measure: Non-attachment
time frame: Up to 2.5 months before treatment, 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Non-attachment will be measures with Non-Attachment Scale (Sahdra, Shaver, & Brown, 2010).
measure: Expectations of change with treatment
time frame: Expectations Measure: after session 1. For Patient Global Impression of Change Scale: 2-4 weeks post treatment, 6 months post treatment, and 12 months post treatment.
description: Will be measured with the Expectations Measure [a two-item questionnaire completed following the session 1, designed for and used in our approved mindfulness-based treatment study for provoked vestibulodynia (H12-02358)], and participants' impressions of change with treatment with the Patient Global Impression of Change Scale - Revised (adapted from Hurst & Bolton, 2004; as used in H12-02358).
arm group label: MBCT group
arm group type: Experimental
description: Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
arm group label: Support group
arm group type: Active Comparator
description: Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
intervention type: Behavioral
intervention name: Mindfulness-based treatment
description: The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
arm group label: MBCT group
intervention type: Behavioral
intervention name: Sex therapy, education, and support treatment
description: The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
arm group label: Support group
criteria: 
gender: Female
minimum age: 19 Years
maximum age: 65 Years
healthy volunteers: No
last name: Lori A Brotto, PhD
role: Principal Investigator
affiliation: University of British Columbia
facility: 
country: Canada
responsible party type: Principal Investigator
investigator affiliation: University of British Columbia
investigator full name: Lori Brotto
investigator title: Professor, UBC Department of Gynaecology
submitted: November 1, 2022
returned: September 12, 2023